Evidence map›Paper›PMID 11901193›Full record

ArticleThe Journal of experimental medicine2002

Complement activation selectively potentiates the pathogenicity of the IgG2b and IgG3 isotypes of a high affinity anti-erythrocyte autoantibody.

Samareh Azeredo da Silveira, Shuichi Kikuchi, Liliane Fossati-Jimack, Thomas Moll, Takashi Saito, J Sjef Verbeek, Marina Botto, Mark J Walport, Michael Carroll, Shozo Izui

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02245867 (Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis), which is not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02245867 phase1completednot on this mapstarted 2014, after this paper: background citation

Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

TypeinterventionalSponsorAlexion Pharmaceuticals, Inc.Ran2014 to 2017Enrolled30ConditionsAL AmyloidosisArmsChimeric Fibril-Reactive Monoclonal Anti-body 11-1F4
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 147 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. CD4Mediators of inflammation · 2022
    Article
  11. Article
  12. Frontiers in immunology · 2020
    Article
  13. Integrin β1 Promotes the Interaction of Murine IgG3 with Effector Cells.Journal of immunology (Baltimore, Md. : 1950) · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 5 countries.

Samareh Azeredo da SilveiraDepartment of Pathology, University of Geneva, 1211 Geneva 4, Switzerland.
Shuichi Kikuchi
Liliane Fossati-Jimack
Thomas Moll
Takashi Saito
J Sjef Verbeek
Marina Botto
Mark J Walport
Michael Carroll
Shozo Izui
University of Geneva · CHHammersmith Hospital · GBChiba University · JPHarvard University · USLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

By generating four IgG isotype-switch variants of the high affinity 34-3C anti-erythrocyte autoantibody, and comparing them to the IgG variants of the low affinity 4C8 anti-erythrocyte autoantibody that we have previously studied, we evaluated in this study how high affinity binding to erythrocytes influences the pathogenicity of each IgG isotype in relation to the respective contributions of Fcgamma receptor (FcgammaR) and complement. The 34-3C autoantibody opsonizing extensively circulating erythrocytes efficiently activated complement in vivo (IgG2a = IgG2b > IgG3), except for the IgG1 isotype, while the 4C8 IgG autoantibody failed to activate complement. The pathogenicity of the 34-3C autoantibody of IgG2b and IgG3 isotypes was dramatically higher (>200-fold) than that of the corresponding isotypes of the 4C8 antibody. This enhanced activity was highly (IgG2b) or totally (IgG3) dependent on complement. In contrast, erythrocyte-binding affinities only played a minor role in in vivo hemolytic activities of the IgG1 and IgG2a isotypes of 34-3C and 4C8 antibodies, where complement was not or only partially involved, respectively. The remarkably different capacities of four different IgG isotypes of low and high affinity anti-erythrocyte autoantibodies to activate FcgammaR-bearing effector cells and complement in vivo demonstrate the role of autoantibody affinity maturation and of IgG isotype switching in autoantibody-mediated pathology.

Indexed as

Anemia, Hemolytic, AutoimmuneAnimalsAutoantibodiesComplement ActivationErythrocytesImmunoglobulin Class SwitchingImmunoglobulin GMiceMice, Inbred BALB CReceptors, IgGAutoantibodiesImmunoglobulin GReceptors, IgG

Identifiers

PMID11901193
PMCPMC2193744
OpenAlexW2155074186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.